Unnamed: 0,title,date,stock,sentiment
1034883.0,77 Biggest Movers From Yesterday,2020-04-01 04:31:00-04:00,PRQR,neutral
1034884.0,ProQR Therapeutics Filing Shows Registration For $75M Common Stock Offering,2020-03-31 16:55:00-04:00,PRQR,neutral
1034885.0,Afternoon Market Stats in 5 Minutes,2020-03-31 12:57:00-04:00,PRQR,neutral
1034886.0,56 Stocks Moving In Tuesday's Mid-Day Session,2020-03-31 12:27:00-04:00,PRQR,neutral
1034887.0,ProQr Reports  Findings From Three-Month Interim Analysis  Of Phase 1/2 Steller Trial Of QR-421a In Adults With Usher Syndrom And nsRP,2020-03-31 06:02:00-04:00,PRQR,neutral
1034888.0,"The Week Ahead In Biotech: Clinical Readouts, COVID-19 News Flow In Focus Amid Continuing Uncertainty",2020-03-29 12:10:00-04:00,PRQR,negative
1034889.0,"The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment",2020-03-17 08:48:00-04:00,PRQR,neutral
1034890.0,108 Biggest Movers From Yesterday,2020-03-03 04:57:00-05:00,PRQR,neutral
1034891.0,24 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-02-26 08:01:00-05:00,PRQR,neutral
1034892.0,ProQR Q4 EPS €0.39,2020-02-26 07:23:00-05:00,PRQR,neutral
1034893.0,ProQR Therapeutics Reports Receives Rare Pediatric Disease Designation For QR-421a,2020-01-30 07:10:00-05:00,PRQR,neutral
1034894.0,26 Stocks Moving in Wednesday's Pre-Market Session,2019-12-18 07:58:00-05:00,PRQR,neutral
1034895.0,74 Biggest Movers From Yesterday,2019-12-17 05:35:00-05:00,PRQR,neutral
1034896.0,40 Stocks Moving In Monday's Mid-Day Session,2019-12-16 12:10:00-05:00,PRQR,neutral
1034897.0,ProQR Announces First Patient Dosed In Phase 1/2 Aurora Trial Of QR-1123 For Autosomal Dominant Retinitis Pigmentosa,2019-12-11 07:14:00-05:00,PRQR,neutral
1034898.0,52 Biggest Movers From Friday,2019-12-02 04:44:00-05:00,PRQR,neutral
1034899.0,ProQR Therapeutics Reports Received Orphan Drug Designation For QR-1123 For Autosomal Dominant Retinitis Pigmentosa,2019-11-21 07:07:00-05:00,PRQR,neutral
1034900.0,63 Biggest Movers From Yesterday,2019-11-21 04:49:00-05:00,PRQR,neutral
1034901.0,"Citi Maintains Buy on ProQR Therapeutics, Lowers Price Target to $33",2019-11-19 08:20:00-05:00,PRQR,negative
1034902.0,ProQR Therapeutics Q3 EPS €(0.31) Down From €(0.18) YoY,2019-11-06 08:14:00-05:00,PRQR,neutral
1034903.0,38 Biggest Movers From Yesterday,2019-10-22 06:42:00-04:00,PRQR,neutral
1034904.0,32 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-10-18 08:34:00-04:00,PRQR,neutral
1034905.0,ProQR Reports Closing Of 9.09M Share Common Stock Offering At $5.50/Share For Gross Proceeds ~$57.5M,2019-10-18 08:21:00-04:00,PRQR,negative
1034906.0,Stocks That Hit 52-Week Lows On Wednesday,2019-10-16 10:55:00-04:00,PRQR,negative
1034907.0,17 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-10-16 07:57:00-04:00,PRQR,neutral
1034908.0,23 Stocks Moving in Wednesday's Pre-Market Session,2019-10-16 07:40:00-04:00,PRQR,neutral
1034909.0,"The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch",2019-10-16 07:06:00-04:00,PRQR,positive
1034910.0,"ProQR Therapeutics 6-K Shows Cash, Cash Equivalents Of €74.8M As Of Sep. 30, 2019",2019-10-16 06:19:00-04:00,PRQR,neutral
1034911.0,ProQR Prices 9.09M Share Underwritten Public Offering of Ordinary Shares @$5.50/Share,2019-10-16 03:11:00-04:00,PRQR,positive
1034912.0,ProQR Therapeutics shares are trading lower after the company announced a $50 million common stock offering.,2019-10-15 16:19:00-04:00,PRQR,neutral
1034913.0,ProQR Reports $50M Common Stock Offering,2019-10-15 16:14:00-04:00,PRQR,neutral
1034914.0,ProQR Receives Rare Pediatric Disease Designation From FDA For Sepofarsen For The Treatment Of LCA10,2019-10-15 16:10:00-04:00,PRQR,neutral
1034915.0,"ProQR Shares Fall To Session Low, Down 2.9%, Despite Traders Circulating JMP Comments Suggesting Positive Data For Sepofarsen Bodes Well For LCA10 Trial; Firm Reiterates Market Outperform, $25 Price Target",2019-10-10 11:26:00-04:00,PRQR,positive
1034916.0,5 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-10-10 08:11:00-04:00,PRQR,neutral
1034917.0,"The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO",2019-10-10 07:31:00-04:00,PRQR,neutral
1034918.0,ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients,2019-10-10 06:01:00-04:00,PRQR,positive
1034919.0,28 Stocks Moving In Wednesday's Mid-Day Session,2019-10-09 12:56:00-04:00,PRQR,neutral
1034920.0,Mid-Day Market Update: Crude Oil Up 1%; James River Group Shares Plunge,2019-10-09 12:55:00-04:00,PRQR,negative
1034921.0,Mid-Morning Market Update: Markets Open Higher; Johnson & Johnson Hit With $8B Verdict In Risperdal Lawsuit,2019-10-09 10:27:00-04:00,PRQR,negative
1034922.0,"The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines",2019-10-01 08:10:00-04:00,PRQR,negative
1034923.0,Stocks That Hit 52-Week Lows On Monday,2019-09-30 11:20:00-04:00,PRQR,negative
1034924.0,"The Daily Biotech Pulse: PhaseBio Leaps On Trial Results, Pacira Set To Join SmallCap 600 Index, Positive Readout For Amgen's Blood Cancer Drug",2019-09-25 07:13:00-04:00,PRQR,positive
1034925.0,"The Daily Biotech Pulse: Sandoz Recalls Ulcer Drug, Anchiano Strikes Agreement With ADT Pharma, Proteon Announces Reverse Merger",2019-09-24 08:12:00-04:00,PRQR,positive
1034926.0,Stocks That Hit 52-Week Lows On Monday,2019-09-23 13:35:00-04:00,PRQR,negative
1034927.0,ProQR Recieves Fast Track Designation from the FDA for QR-1123,2019-09-09 07:09:00-04:00,PRQR,neutral
1034928.0,"The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books",2019-09-04 07:08:00-04:00,PRQR,positive
1034929.0,"The Daily Biotech Pulse: EC Approves Roche's Tecentriq For Breast Cancer, Trevena On Track For NDA Resubmission, Edap Earnings",2019-08-29 07:38:00-04:00,PRQR,negative
1034930.0,ProQR Reports Clearance Of Investigational New Drug to Start Trial Of QR-1123 In Patients With Autosomal Dominant Retinitis Pigmentosa,2019-08-12 07:13:00-04:00,PRQR,neutral
1034931.0,ProQR Therapeutics Q2 EPS €(0.30) Down From €(0.23) YoY,2019-08-07 07:30:00-04:00,PRQR,neutral
1034932.0,ProQR Therapeutics shares are trading higher after the company's sepofarsen (QR-110) drug candidate was granted access to the PRIority MEdicines (PRIME) program by the European Medicines Agency (EMA).,2019-07-29 11:09:00-04:00,PRQR,positive
1034933.0,European Medicines Agency Grants PRIME Access To ProQR's Sepofarsen For Leber's Congenital Amaurosis 10,2019-07-29 07:21:00-04:00,PRQR,positive
1034934.0,40 Biggest Movers From Friday,2019-07-15 05:47:00-04:00,PRQR,neutral
1034935.0,36 Stocks Moving In Friday's Mid-Day Session,2019-07-12 12:38:00-04:00,PRQR,neutral
1034936.0,55 Biggest Movers From Yesterday,2019-07-12 05:18:00-04:00,PRQR,neutral
1034937.0,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,2019-07-11 10:36:00-04:00,PRQR,negative
1034938.0,ProQR Highlights Presentation On QR-421a Program In Ophthalmology At Usher Syndrome Coalition Conference In July,2019-07-02 07:04:00-04:00,PRQR,neutral
1034939.0,ProQR Therapeutics Q1 EPS $(0.36) Beats $(0.41) Estimate,2019-05-08 07:51:00-04:00,PRQR,neutral
1034940.0,ProQR Therapeutics N.V. - Ordinary Shares Q1 EPS €(0.36) vs €(0.33) In Same Qtr. Last Year,2019-05-08 07:39:00-04:00,PRQR,positive
1034941.0,"Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'",2019-04-23 11:52:00-04:00,PRQR,positive
1034942.0,ProQr Expects Data From its Phase 2/3 Illuminate Trial at Year End 2020,2019-04-15 07:06:00-04:00,PRQR,neutral
1034943.0,ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10,2019-04-15 07:06:00-04:00,PRQR,neutral
1034944.0,ProQR Therapeutics Says it Will Spin Out its Dystrophic Epidermolysis Bullosa Business INto a Newly Formed Company,2019-03-26 16:02:00-04:00,PRQR,neutral
1034945.0,ProQR Doses First Patient In Phase 1/2 STELLAR Trial Of QR-421a For Usher Syndrome Type 2,2019-03-11 08:03:00-04:00,PRQR,neutral
1034946.0,ProQR Q4 EPS €(0.33) Up From €(0.39) YoY,2019-02-27 07:16:00-05:00,PRQR,neutral
1034947.0,71 Biggest Movers From Yesterday,2019-02-20 04:49:00-05:00,PRQR,neutral
1034948.0,50 Biggest Movers From Yesterday,2019-02-06 05:03:00-05:00,PRQR,neutral
1034949.0,55 Biggest Movers From Yesterday,2019-01-11 05:45:00-05:00,PRQR,neutral
1034950.0,40 Stocks Moving In Thursday's Mid-Day Session,2019-01-10 12:44:00-05:00,PRQR,neutral
1034951.0,ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber's Congenital Amaurosis 10,2019-01-07 07:06:00-05:00,PRQR,positive
1034952.0,66 Biggest Movers From Yesterday,2019-01-03 05:00:00-05:00,PRQR,neutral
1034953.0,45 Stocks Moving In Wednesday's Mid-Day Session,2019-01-02 12:21:00-05:00,PRQR,neutral
1034954.0,ProQR Therapeutics shares are trading higher after the company received Fast Track Destination from the FDA for QR-421a.,2019-01-02 11:02:00-05:00,PRQR,positive
1034955.0,16 Stocks Moving In Wednesday's Pre-Market Session,2019-01-02 08:03:00-05:00,PRQR,neutral
1034956.0,A Peek Into The Markets: US Stock Futures Tumble,2019-01-02 07:37:00-05:00,PRQR,neutral
1034957.0,ProQR Receives Fast Track Designation From FDA For QR-421a For Usher Syndrome Type 2,2019-01-02 07:11:00-05:00,PRQR,neutral
1034958.0,The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results,2018-12-23 10:37:00-05:00,PRQR,neutral
1034959.0,"UPDATE: ProQR Says Phase 1/2 PQ-110-001 Study Of QR-110 Will Be Completed, In Parallel With Phase 2/3 ILLUMINATE Study, Expected To Be Initiated In 1H'19",2018-12-17 11:54:00-05:00,PRQR,neutral
1034960.0,ProQR Issues Release Highlighting Publication Of Previously-Published QR-110 Data For Leber's Congential Amaurosis 10 In 'Nature Medicine',2018-12-17 11:53:00-05:00,PRQR,neutral
1034961.0,ProQR Wins a EUR 4.7M Innovation Credit From the Dutch Government,2018-12-10 07:13:00-05:00,PRQR,positive
1034962.0,ProQR Announces Clearance Of IND To Start Clinical Trial Of QR-421a In Usher Syndrome Type 2 Patients,2018-12-04 07:19:00-05:00,PRQR,neutral
1034963.0,"Benzinga's Top Upgrades, Downgrades For November 14, 2018",2018-11-14 09:19:00-05:00,PRQR,positive
1034964.0,"Cantor Fitzgerald Initiates Coverage On ProQR Therapeutics with Overweight Rating, Announces $40 Price Target",2018-11-14 08:42:00-05:00,PRQR,negative
1034965.0,ProQR Therapeutics Filing Shows Registration For $300M Mixed Securities Offering,2018-11-07 18:37:00-05:00,PRQR,positive
1034966.0,"Stocks Which Set New 52-Week High Yesterday, Mon., Nov. 5, 2018",2018-11-06 09:26:00-05:00,PRQR,neutral
1034967.0,76 Biggest Movers From Yesterday,2018-11-02 06:12:00-04:00,PRQR,neutral
1034968.0,"UPDATE: ProQR Granted Exclusive Global License To QR-1123, Relevant Patents For Upfront Payment Of $2.5M At $22.23/Share",2018-10-29 07:34:00-04:00,PRQR,positive
1034969.0,ProQR Therapeutics Reports In-Licenses Global Rights To Ophthalmology Drug Candidate From Ionis Pharma,2018-10-29 07:34:00-04:00,PRQR,neutral
1034970.0,"Benzinga's Top Upgrades, Downgrades For September 19, 2018",2018-09-19 09:16:00-04:00,PRQR,positive
1034971.0,"Evercore ISI Group Initiates Coverage On ProQR Therapeutics with Outperform Rating, Announces $35 Price Target",2018-09-19 07:50:00-04:00,PRQR,neutral
1034972.0,"Stocks Which Set New 52-Week High Yesterday, September 17th",2018-09-18 09:25:00-04:00,PRQR,neutral
1034973.0,44 Biggest Movers From Friday,2018-09-17 05:10:00-04:00,PRQR,neutral
1034974.0,48 Biggest Movers From Yesterday,2018-09-13 05:01:00-04:00,PRQR,neutral
1034975.0,38 Stocks Moving In Wednesday's Mid-Day Session,2018-09-12 12:28:00-04:00,PRQR,neutral
1034976.0,"Stocks Which Set New 52-Week High Yesterday, September 11th",2018-09-12 12:17:00-04:00,PRQR,neutral
1034977.0,"The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt",2018-09-12 08:26:00-04:00,PRQR,positive
1034978.0,48 Biggest Movers From Yesterday,2018-09-12 05:20:00-04:00,PRQR,neutral
1034979.0,38 Stocks Moving In Tuesday's Mid-Day Session,2018-09-11 12:31:00-04:00,PRQR,neutral
1034980.0,"The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet",2018-09-11 08:25:00-04:00,PRQR,negative
1034981.0,51 Biggest Movers From Yesterday,2018-09-11 05:05:00-04:00,PRQR,neutral
1034982.0,25 Stocks Moving In Friday's Pre-Market Session,2018-09-07 08:05:00-04:00,PRQR,neutral
1034983.0,55 Biggest Movers From Yesterday,2018-09-07 05:17:00-04:00,PRQR,neutral
1034984.0,ProQR Prices 5.75M Share Underwritten Public Offering of Ordinary Shares @$15.75/Share,2018-09-07 04:22:00-04:00,PRQR,positive
1034985.0,40 Stocks Moving In Thursday's Mid-Day Session,2018-09-06 12:31:00-04:00,PRQR,neutral
1034986.0,"Stocks Which Set New 52-Week High Yesterday, September 5th",2018-09-06 08:48:00-04:00,PRQR,neutral
1034987.0,"The Daily Biotech Pulse: Novartis Divestment, Eyepoint's Drug Gets Coverage, Spectrum's Robust Data",2018-09-06 08:28:00-04:00,PRQR,positive
1034988.0,21 Stocks Moving In Thursday's Pre-Market Session,2018-09-06 08:01:00-04:00,PRQR,neutral
1034989.0,A Peek Into The Markets: US Stock Futures Rise Ahead Of Economic Reports,2018-09-06 06:52:00-04:00,PRQR,neutral
1034990.0,"10 Stocks To Watch For September 6, 2018",2018-09-06 05:34:00-04:00,PRQR,neutral
1034991.0,54 Biggest Movers From Yesterday,2018-09-06 05:13:00-04:00,PRQR,neutral
1034992.0,ProQR Therapeutics shares are down 88.8% after the company announced a $75 million offering.,2018-09-05 16:59:00-04:00,PRQR,positive
1034993.0,5 Stocks Moving In Wednesday's After-Hours Session,2018-09-05 16:59:00-04:00,PRQR,neutral
1034995.0,Mid-Afternoon Market Update: Crude Oil Down 1.5%; Histogenics Shares Plunge,2018-09-05 14:32:00-04:00,PRQR,negative
1034996.0,40 Stocks Moving In Wednesday's Mid-Day Session,2018-09-05 12:40:00-04:00,PRQR,neutral
1034997.0,Mid-Day Market Update: NASDAQ Down Over 100 Points; ProQR Therapeutics Shares Surge,2018-09-05 12:04:00-04:00,PRQR,positive
1034998.0,Mid-Morning Market Update: Markets Open Lower; HD Supply Earnings Top Expectations,2018-09-05 10:29:00-04:00,PRQR,negative
1034999.0,"Stocks Which Set New 52-Week High Yesterday, September 4th",2018-09-05 10:22:00-04:00,PRQR,neutral
1035000.0,ProQR Therapeutics shares are up 74.8% premarket after the company announced positive interim results from its Phase 1/2 trial of QR-110 in LCA10 eye disease.,2018-09-05 09:22:00-04:00,PRQR,positive
1035001.0,Benzinga Pro's 6 Stocks To Watch Today,2018-09-05 09:15:00-04:00,PRQR,neutral
1035002.0,"The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results",2018-09-05 08:28:00-04:00,PRQR,positive
1035003.0,26 Stocks Moving In Wednesday's Pre-Market Session,2018-09-05 08:01:00-04:00,PRQR,neutral
1035005.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings",2018-09-02 09:41:00-04:00,PRQR,neutral
1035006.0,ProQR To Present Interim Phase 1/2 Results For QR-110 In Leber's Congenital Amaurosis 10 At Symposium for Retinal Degeneration on Sept. 5th,2018-08-15 07:10:00-04:00,PRQR,neutral
1035007.0,"Stocks Which Set New 52-Week High Yesterday, August 9th",2018-08-10 10:03:00-04:00,PRQR,neutral
1035008.0,"Stocks Which Set New 52-Week High Yesterday, August 8th",2018-08-09 11:03:00-04:00,PRQR,neutral
1035009.0,ProQR Announces the Initiation of a Phase 1/2 Trial for QR-313,2018-06-28 07:09:00-04:00,PRQR,neutral
1035010.0,ProQR Receives Up To $5 Million In Partnership With EB Research Partnership And EB Medical Research Foundation To Develop QR-313 For Treatment Of Dystrophic Epidermolysis Bullosa,2018-06-12 07:03:00-04:00,PRQR,neutral
1035011.0,44 Biggest Movers From Yesterday,2018-06-05 05:27:00-04:00,PRQR,neutral
1035012.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-13 10:06:00-04:00,PRQR,neutral
1035013.0,ProQR Q1 EPS €(0.34) vs €(0.45) In Same Qtr. Last Year,2018-05-09 07:22:00-04:00,PRQR,neutral
1035014.0,"ProQR Says 8 of 12 Patients Have Been Enrolled in its Phase 1/2 Trial of QR-110, Says On Track to Deliver Data in 2H 2018",2018-04-23 07:03:00-04:00,PRQR,neutral
1035015.0,"Benzinga's Top Upgrades, Downgrades For April 5, 2018",2018-04-05 09:23:00-04:00,PRQR,positive
1035016.0,"Chardan Capital Initiates Coverage On ProQR Therapeutics with Buy Rating, Announces $4.50 Price Target",2018-04-05 08:26:00-04:00,PRQR,neutral
1035017.0,ProQR Reports Q4 EPS €(0.39) vs €(0.38) In Same Qtr. Last Year,2018-02-28 07:09:00-05:00,PRQR,neutral
1035018.0,Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR's candidate QR-421a for Usher syndrome type 2A,2018-02-12 07:12:00-05:00,PRQR,negative
1035019.0,"ProQR, Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR's Axiomer technology",2018-01-08 07:25:00-05:00,PRQR,neutral
1035020.0,ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa,2017-11-29 07:08:00-05:00,PRQR,neutral
1035021.0,ProQr Therapeutics Shares Moving Higher As Traders Pass Link That Suggest  Co. Has Received EU Orphan Drug Status For Treatment of Retinitis Pigmentosa,2017-11-21 15:06:00-05:00,PRQR,positive
1035022.0,ProQR Reports Q3 EPS EUR (0.42),2017-11-20 07:04:00-05:00,PRQR,neutral
1035023.0,46 Biggest Movers From Yesterday,2017-11-15 05:04:00-05:00,PRQR,neutral
1035024.0,42 Stocks Moving In Tuesday's Mid-Day Session,2017-11-14 12:25:00-05:00,PRQR,neutral
1035025.0,ProQR Prices $20M Offering at $3.25/Share,2017-11-14 07:45:00-05:00,PRQR,neutral
1035026.0,"ProQR Announces Offering Common Stock, No Size Disclosed",2017-11-13 16:01:00-05:00,PRQR,negative
1035027.0,ProQr Doses First Patient in LCA Trial of QR-110,2017-11-13 07:08:00-05:00,PRQR,neutral
1035028.0,"ProQR Therapeutics Shares Sold Off Throughout Tuesday's Trading Session Following 10% After-Hours Move Higher Mon. Amid Data For QR-010 Phase 1b Trial; Stock Down 12+% Tues. Afternoon; Leerink, HC Wainwright Each Made Positive Comments Earlier",2017-09-26 15:10:00-04:00,PRQR,positive
1035029.0,15 Biggest Mid-Day Losers For Tuesday,2017-09-26 13:04:00-04:00,PRQR,negative
1035030.0,"What's The Thesis On ProQR Now, After Promising Phase 1 Data?",2017-09-26 11:41:00-04:00,PRQR,positive
1035031.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-09-26 08:10:00-04:00,PRQR,neutral
1035032.0,"ProQR Announces 'Positive' Top-line Data From Phase 1b Study Of QR-010, Clinically Meaningful Improvement In CF Respiratory Systems, Safe And Well-Tolerated",2017-09-25 16:01:00-04:00,PRQR,positive
1035033.0,REMINDER: ProQR Phase 1b Topline Date Due Today For Translarna,2017-09-25 09:28:00-04:00,PRQR,neutral
1035034.0,12 Biggest Mid-Day Gainers For Thursday,2017-09-21 12:28:00-04:00,PRQR,neutral
1035035.0,28 Stocks Moving In Wednesday's Pre-Market Session,2017-09-20 08:08:00-04:00,PRQR,neutral
1035036.0,10 Biggest Mid-Day Gainers For Tuesday,2017-09-19 12:27:00-04:00,PRQR,neutral
1035037.0,ProQR Recieves Orphan Drug Designation from the FDA for QR-313,2017-09-19 07:01:00-04:00,PRQR,neutral
1035038.0,"ProQR Spins out Amylon Therapeutics as a Private Company with Funding from Institutional and Private Investors, Terms Not Disclosed",2017-09-12 07:03:00-04:00,PRQR,neutral
1035039.0,ProQR Therapeutics' QRX-421 Granted Orphan Drug Designation by the FDA and EMA,2017-09-05 07:07:00-04:00,PRQR,positive
1035040.0,"Volume Comes Into ProQR Therapeutics Shares, Stock Spikes ~7% Following Trader Circulation Of Report A Co. Drug May Have Won Orphan Drug Designation In EU",2017-08-30 14:54:00-04:00,PRQR,positive
1035041.0,ProQR Therapeutics Reports Q2 €(0.47) vs €(0.43) In Same Qtr. Last Year,2017-08-16 07:04:00-04:00,PRQR,neutral
1035042.0,20 Stocks Moving In Wednesday's Pre-Market Session,2017-07-05 08:15:00-04:00,PRQR,neutral
1035043.0,"ProQR Announces QR$X 4-11 For Usher Syndrome Receives Orphan Drug Designation From FDA, EMA",2017-07-05 07:00:00-04:00,PRQR,neutral
1035044.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-06-27 08:21:00-04:00,PRQR,neutral
1035045.0,"ProQR to Provide Update on Pipeline; Introduces Axiomer, a Novel Proprietary RNA Technology -",2017-06-15 07:21:00-04:00,PRQR,positive
1035046.0,"ProQR Will Present QR-010 Data At European CF Society Conference, Sees Topline Safety, Exploratory Efficacy Data From Multiple Dose Cohorts In Phase 1B Trial Expected In Sept. 2017",2017-06-08 09:09:00-04:00,PRQR,positive
1035047.0,ProQR Therapeutics Receives Fast Track Designation for QR-110,2017-05-31 07:11:00-04:00,PRQR,neutral
1035048.0,ProQR Q1 EPS $(0.45) vs $(0.52) Est,2017-05-17 07:05:00-04:00,PRQR,neutral
1035049.0,ProQR Therapeutics Reports Clearance of IND App to Begin Clinical Trial for QR-110 in Leber's Congenital Amaurosis Type 10 Patients,2017-04-27 07:25:00-04:00,PRQR,neutral
1035050.0,ProQR Reports Q4 $(0.38) vs. $(0.53) Est.,2017-02-28 07:14:00-05:00,PRQR,neutral
1035051.0,ProQR Reports Q3 EPS E$(0.43) vs. Est. $(0.55),2016-11-14 07:19:00-05:00,PRQR,neutral
1035052.0,Mid-Morning Market Update: Markets Open Higher; Twitter Beats Q3 Expectations,2016-10-27 10:09:00-04:00,PRQR,neutral
1035053.0,ProQR Shares Spiking 40%,2016-10-27 09:24:00-04:00,PRQR,positive
1035054.0,UPDATE: ProQR Therapeutics Presenting Phase 1b Prelim Data At North American Cystic Fibrosis Conference,2016-10-27 08:52:00-04:00,PRQR,neutral
1035055.0,ProQR Therapeutics +28.4% Premarket @ $7.90; Co Announced QR-010 Met Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis Patients,2016-10-27 08:49:00-04:00,PRQR,neutral
1035056.0,ProQR Therapeutics Shares Up 26% Premarket After Co. Reports QR-010 Meets Primary Endpoint in Study of Homozygous F508del CF Patients,2016-10-27 08:49:00-04:00,PRQR,positive
1035057.0,14 Stocks Which Plummeted Three Days On Increasing Volume,2016-10-17 06:40:00-04:00,PRQR,neutral
1035058.0,Janney Capital Initiates Coverage on ProQR Therapeutics at Neutral,2016-09-29 06:13:00-04:00,PRQR,neutral
1035059.0,"ProQR Q2 EPS EUR(0.43) vs EUR(0.48) est, Revenue EUR 589K vs EUR 110K est",2016-08-17 07:03:00-04:00,PRQR,neutral
1035060.0,ProQR Reports Received Fast Track Designation for QR-010 for Cystic Fibrosis,2016-07-19 07:05:00-04:00,PRQR,neutral
1035061.0,ProQR Therapeutics Has Limited Downside Or Upside According to Chardan,2016-06-20 08:39:00-04:00,PRQR,negative
1035062.0,"Chardan Capital Initiates Coverage on ProQR Therapeutics at Neutral, Announces $4.50 PT",2016-06-20 06:02:00-04:00,PRQR,neutral
1035063.0,"ProQR's Drug Candidate QR-110 for Leber's Congenital Amaurosis Type 10 Receives EMA, FDA Orphan Drug Designation; Grants 7 Years Market Exclusivity In U.S. And 10 Years In Europe",2016-06-01 07:10:00-04:00,PRQR,positive
1035064.0,ProQR Q1 EPS EUR ($0.44) vs EUR ($0.41) est,2016-05-18 07:05:00-04:00,PRQR,neutral
1035065.0,Prudential Financial Inc Reports 11.5% Passive Stake In Proqr Therapeutics in 13G,2016-04-11 16:12:00-04:00,PRQR,positive
1035066.0,"Jennison Associates Reports 11.5% Passive Stake In Proqr Therapeutics as of March 31, 2016  in 13G-",2016-04-08 14:33:00-04:00,PRQR,positive
1035067.0,"JMP Securities Maintains Market Outperform on ProQR Therapeutics, Lowers PT to $14.00",2016-03-15 06:40:00-04:00,PRQR,positive
1035068.0,ProQR Reports Q4 EPS E$(0.26) vs. Est. E$(0.39),2016-02-17 07:11:00-05:00,PRQR,neutral
1035069.0,Mid-Afternoon Market Update: US Stocks Down; GameStop Shares Dip On Weak Results,2015-11-23 15:04:00-05:00,PRQR,negative
1035070.0,Mid-Day Market Update: TeleCommunication Systems Surges On Acquisition News; ProQR Therapeutics Shares Slide,2015-11-23 12:28:00-05:00,PRQR,positive
1035071.0,Mid-Morning Market Update: Markets Mostly Flat; Pfizer To Buy Allergan,2015-11-23 10:16:00-05:00,PRQR,neutral
1035072.0,Morning Market Losers,2015-11-23 09:57:00-05:00,PRQR,negative
1035073.0,"ProQR Says Data Now Expected in Mid to Late 2016, Reports Q3 EPS -$0.29",2015-11-23 06:33:00-05:00,PRQR,neutral
1035074.0,"Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now",2015-10-06 14:08:00-04:00,PRQR,neutral
1035075.0,ProQR Announces a Proof-of-Concept Nasal Potential Difference Study of QR-010 is Open for Enrollment,2015-09-14 07:00:00-04:00,PRQR,neutral
1035076.0,ProQR Therapeutics Reports Q2 Loss EURO$0.37 Vs Est Loss EURO$0.34,2015-08-19 08:01:00-04:00,PRQR,negative
1035077.0,ProQR Therapeutics N.V. Begins Enrollment for PQ-010-001 Study,2015-06-26 08:10:00-04:00,PRQR,neutral
1035078.0,ProQR Therapeutics Reports Q1 EPS E$0.01,2015-05-21 07:04:00-04:00,PRQR,neutral
1035079.0,Benzinga's Top Initiations ,2014-10-15 09:20:00-04:00,PRQR,positive
1035080.0,Deutsche Bank Initiates ProQR Therapeutics With Buy,2014-10-15 08:28:00-04:00,PRQR,neutral
1035081.0,"Deutsche Bank Initiates Coverage on ProQR Therapeutics at Buy, Announces $32.00 PT",2014-10-15 06:10:00-04:00,PRQR,neutral
1035082.0,"JMP Securities Initiates Coverage on ProQR Therapeutics at Market Outperform, Announces $36.00 PT",2014-10-14 05:47:00-04:00,PRQR,positive
1035083.0,"Midday Losers From October 13 - GoPro, Aerohive Networks, Lithia Motors And More",2014-10-13 14:18:00-04:00,PRQR,negative
1035084.0,"Leerink Partners Initiates Coverage on ProQR Therapeutics at Outperform, Announces $24.00 PT",2014-10-13 09:28:00-04:00,PRQR,neutral
1035085.0,"HC Waintwright Initiates Coverage on ProQR Therapeutics at Buy, Announces $40.00 PT",2014-10-13 09:28:00-04:00,PRQR,neutral
1035086.0,Benzinga's Top Initiations,2014-10-13 08:51:00-04:00,PRQR,positive
1035087.0,Jefferies Initiates ProQR Therapeutics With Outperform,2014-10-13 08:04:00-04:00,PRQR,neutral
1035088.0,"Jefferies Initiates Coverage on ProQR Therapeutics at Outperform, Announces $24.00 PT",2014-10-13 06:12:00-04:00,PRQR,neutral
1035089.0,"Shares of ProQR Therapeutics Open for Trade at $19.99/Share, IPO Priced at $13",2014-09-18 10:26:00-04:00,PRQR,positive
1035090.0,Expected IPOs For Thursday September 18,2014-09-18 09:24:00-04:00,PRQR,neutral
1035091.0,ProQR Therapeutics Prices 7.5M Share IPO at $13.00/Share,2014-09-18 08:09:00-04:00,PRQR,positive
1035092.0,The Alibaba IPO & Six Other New Issues For The Week Of September 15,2014-09-15 14:55:00-04:00,PRQR,neutral
1035093.0,ProQR Therapeutics Expects 6.25M Share IPO to Price $11-$13/Share,2014-09-08 06:25:00-04:00,PRQR,positive
